Launched a clinical trial to prevent the side effects of COVID-19

The trial, in which IMIM participates, will administer a nutritional supplement rich in immunoglobulins that would reduce, among other side effects, the inflammation caused by SARS-CoV-2.

The trial seeks to reduce the side effects caused by COVID-19 by means of a dietary supplement. Photo by Candace Mathers on Unsplash

The Hospital del Mar Medical Research Institute (IMIM), the Hospital del Mar, the University of California-Davies and the University of Texas have initiated a clinical trial to verify the effectiveness of a dietary supplement rich in bovine immunoglobulins that could help prevent the worst COVID-19 side effects.

This method, which has already proved effective in animal models, could reduce the inflammation caused by SARS-CoV-2, and prevent the progression to severe forms of the disease and the post-COVID syndrome.

“The aim of the treatment is to sequester and help eliminate the virus from one of its main reservoirs in the body, the gut.”
Robert Güerri (IMIM), principal investigator of the trial.

The trial will analyze the data of 420 patients, 280 of whom will take the supplement EnteraGam as a complementary method to the rest of the treatments for the infection. The trial will serve to verify if the positive results observed in animal models treated with bovine serum immunoglobulins can also apply to humans.

Leave a Reply

Your email address will not be published. Required fields are marked *